Abstract: An electromechanical actuator for forced unlocking of a fuzzy jamming fault of a transmission mechanism comprises a bidirectional electromagnetic braking assembly, a circumferential rotating housing assembly, an axial spline bearing assembly, an LVDT linear displacement sensor assembly, a potentiometer linear displacement sensor assembly, and an electromechanical actuator assembly. The axial spline bearing assembly is mounted inside the circumferential rotating housing assembly for a reciprocating linear motion, and the axial spline bearing assembly is connected to an output rotating shaft of the electromechanical actuator assembly to form a spiral transmission pair; the bidirectional electromagnetic braking assembly is actively energized to generate radial and axial attraction forces, so that the circumferential rotating housing assembly is disengaged from a fixed connection with the electromechanical actuator assembly to rotate.

Abstract: The present disclosure provides protein-macromolecule conjugates, releasable linkers, and macromolecules, as defined herein. The disclosed conjugates provide unique properties that ae based at least upon the properties of linker and number of linker-Macromolecule moieties. Also provided herein are a method of synthesis and use of conjugates in treating diseases and disorders.

Abstract: The invention provides human monoclonal antibodies that specifically bind to PD-1 with high affinity. The anti-PD-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed. The synthetic antibody libraries used to select for the high affinity anti-PD-1 monoclonal antibodies were made by replacing the light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR 2 and CDR 3 of phage libraries from the preliminary screening, and the high affinity anti-PD-1 monoclonal antibodies were selected. The human anti-PD-1 monoclonal antibodies have high affinity and inhibit the binding of PD-1 to its ligand PD-L1. The antibodies can be used for treating tumor, inflammation and autoimmune diseases.

Abstract: A window air conditioner is provided. The window air conditioner includes an air conditioner body; and a sealing plate assembly disposed at at least one side of the air conditioner body and including a fixed sealing plate group and a sliding sealing plate group connected with the fixed sealing plate group in a sealing manner, in which the fixed sealing plate group is disposed on a side wall of the air conditioner body, and the sliding sealing plate group is disposed at a side of the fixed sealing plate group away from the air conditioner body slidably in a direction approaching to or moving away from the air conditioner body.

Abstract: A window air conditioner is provided. The window air conditioner includes an air conditioner body configured to be mounted to a mounting window; and a heat-insulation sealing assembly having at least two layers and provided between the air conditioner body and the mounting window to insulate an inside of the mounting window from an outside of the mounting window.

Abstract: The invention provides human monoclonal antibodies that specifically bind to PD-1 with high affinity. The anti-PD-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed. The synthetic antibody libraries used to select for the high affinity anti-PD-1 monoclonal antibodies were made by replacing the light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR 2 and CDR 3 of phage libraries from the preliminary screening, and the high affinity anti-PD-1 monoclonal antibodies were selected. The human anti-PD-1 monoclonal antibodies have high affinity and inhibit the binding of PD-1 to its ligand PD-L1. The antibodies can be used for treating tumor, inflammation and autoimmune diseases.

Abstract: The invention provides human monoclonal antibodies that specifically bind to PD-1 with high affinity. The anti-PD-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed. The synthetic antibody libraries used to select for the high affinity anti-PD-1 monoclonal antibodies were made by replacing the light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR 2 and CDR 3 of phage libraries from the preliminary screening, and the high affinity anti-PD-1 monoclonal antibodies were selected. The human anti-PD-1 monoclonal antibodies have high affinity and inhibit the binding of PD-1 to its ligand PD-L1. The antibodies can be used for treating tumor, inflammation and autoimmune diseases.

Abstract: A window air conditioner is provided. The window air conditioner includes an air conditioner body; and a sealing plate assembly disposed at at least one side of the air conditioner body and including a fixed sealing plate group and a sliding sealing plate group connected with the fixed sealing plate group in a sealing manner, in which the fixed sealing plate group is disposed on a side wall of the air conditioner body, and the sliding sealing plate group is disposed at a side of the fixed sealing plate group away from the air conditioner body slidably in a direction approaching to or moving away from the air conditioner body.

Abstract: A window air conditioner is provided. The window air conditioner includes an air conditioner body configured to be mounted to a mounting window; and a heat-insulation sealing assembly having at least two layers and provided between the air conditioner body and the mounting window to insulate an inside of the mounting window from an outside of the mounting window.

Abstract: The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.

Abstract: The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.

Abstract: The present invention discloses a can, and provides an enclosure structure for cans with advantages of simple enclosure, low cost, safe and hygienic assurance and opening easiness, as well as a process for machining such an enclosure structure. The present invention solves technical problems in the prior art that pull-outward tabs are easy to break and hard to open while fold-inward tabs have poor safety and hygienic assurance. The enclosure structure of the present invention comprises a top cover of a can, an opening being provided on the top cover. An annular closed boss is provided on an outer edge of the opening; an enclosure covering plate is provided on the annular closed boss; a plastic film is provided on an upper end surface, corresponding to the enclosure covering plate, of the annular closed boss; and the enclosure covering plate is connected in a sealed manner to an upper port of the annular closed boss via the plastic film.

Abstract: A semiconductor fabrication process includes forming a gate dielectric layer (120) overlying a substrate (101) that includes a III-V semiconductor compound. The gate dielectric layer is patterned to produce a gate dielectric structure (121) that has a substantially vertical sidewall (127), e.g., a slope of approximately 45° to 90°. A metal contact structure (130) is formed overlying the wafer substrate. The contact structure is laterally displaced from the gate dielectric structure sufficiently to define a gap (133) between the two. The wafer (100) is heat treated, which causes migration of at least one of the metal elements to form an alloy region (137) in the underlying wafer substrate. The alloy region underlies the contact structure and extends across all or a portion of the wafer substrate underlying the gap. An insulative or dielectric capping layer (140,150) is then formed overlying the wafer and covering the portion of the substrate exposed by the gap.

Abstract: A semiconductor fabrication process includes forming a gate dielectric layer (120) overlying a substrate (101) that includes a III-V semiconductor compound. The gate dielectric layer is patterned to produce a gate dielectric structure (121) that has a substantially vertical sidewall (127), e.g., a slope of approximately 45° to 90°. A metal contact structure (130) is formed overlying the wafer substrate. The contact structure is laterally displaced from the gate dielectric structure sufficiently to define a gap (133) between the two. The wafer (100) is heat treated, which causes migration of at least one of the metal elements to form an alloy region (137) in the underlying wafer substrate. The alloy region underlies the contact structure and extends across all or a portion of the wafer substrate underlying the gap. An insulative or dielectric capping layer (140,150) is then formed overlying the wafer and covering the portion of the substrate exposed by the gap.